Merck Business Development at a Glance

Last Modified Date: February 16, 2018

Merck's blockbuster Keytruda (pembrolizumab) was approved in 2014, and ever since, Merck has been inundated with collaboration offers from other pharma companies looking to pair their best oncology drug with pembrolizumab. These combination therapies accounts for the vast majority of their clinical trial volume and dwarfs out Merck's steady focus on diabetes and infectious diseases.

Merck Stock

Merck & Co., Inc. Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: USD 8 498M
Therapeutic Focus: Cardiovascular Diseases, Diabetes and Endocrinology, Infectious Diseases, Neuroscience, Oncology, Respiratory and Immunology, Vaccines, Women's health


DEAL ACTIVITY

Merck Data

Figure 1. Merck & Co., Inc. In-Licensing Deals and Acquisitions, 2013 through Present (February 2018)

Recent Deal Highlights:

COLLABORATION WITH CUE BIOPHARMA FOR T CELL SUBSETS FOR AUTOIMMUNE DISEASES

Therapeutic Area: Respiratory and Immunology | Date: November 2017

PRESS

COLLABORATION WITH KALVISTA PHARMACEUTICALS FOR INTRAVITREAL INJECTION ASSET AND PLASMA KALLIKREIN ASSETS FOR DIABETIC MACULAR EDEMA

Total: USD 752M | Upfront: USD 37M | Therapeutic Area: Diabetes and Endocrinology | Date: October 2017

PRESS

ACQUISITION OF RIGONTEC FOR RETINOIC ACID-INDUCIBLE GENE 1 IMMUNOTHERAPIES

Total: EUR 464M | Upfront: EUR 115M | Therapeutic Area: Oncology | Date: September 2017

PRESS

R&D PIPELINE

Merck Pipeline

Figure 2. Merck & Co., Inc. R&D Pipeline at present (February 2018)

Products from Recent Deals:

ASTRAZENECA PARTNERED PARP INHIBITOR AND MEK INHIBITOR

Disease Area: Oncology | Status: Aggressive Variant Prostate Cancer Phase II | Non-Small Cell Lung Cancer Combination Therapy Phase II | Metastatic Castration-Resistant Prostate Cancer with Pembrolizumab Phase I

MODERNA PARTNERED MESSENGER RNA-BASED PERSONALIZED CANCER VACCINES

Disease Area: Oncology | Status: Solid Tumors with Pembrolizumab Phase I

BAYER PARTNERED SOLUBLE GUANYLATE CYCLASE MODULATOR

Disease Area: Cardiovascular Diseases | Status: Heart Failure Phase III | Coronary Artery Disease Phase I

BUSINESS DEVELOPMENT TEAM

  • Director, Business Development - China | Qingxi Wang
  • Director, Immuno-Oncology | Hamish Wright
  • Executive Director, BD&L | John Delyani
  • Executive Director, Infectious Disease & Vaccines | Surya Sankuratri
  • Executive Director, Infectious Disease & Vaccines | Stephen de Laszlo
  • Executive Director, Neuroscience | Richard Carter
  • Executive Director, Oncology | Christopher Mortko
  • Executive Director, Oncology & Immuno-Oncology | Maude Tessier
  • Search & Evaluation Lead, Cardiovascular/Metabolism, Women's Health | Rolf Thieringer
  • Search & Evaluation Lead, Cardiovascular/Metabolism, Women's Health | Sanjeev Munshi
  • Search & Evaluation Lead, Immunology & Respiratory | Jose Freire
  • Senior Vice President & Head of BD&L | Ben Thorner
  • VP & Head of Corporate Development | Sunil Patel
  • VP, Business Development & Licensing | Klaus Beck

Business profiles tailored to your asset.